YIDU TECH (02158) has repurchased shares for ten consecutive days, with a total repurchase amount exceeding 1.8 billion Hong Kong Dollars in 2026.

On March 11, YIDU TECH (02158) once again implemented share repurchases, spending over 8 million Hong Kong dollars on the same day, achieving steady repurchases for 10 consecutive trading days. With high-frequency and continuous capital actions, the management team fully demonstrates their strong confidence in the long-term intrinsic value of the company and the development prospects of the AI medical industry, as well as sending a positive signal to the market of the company's stable fundamentals and promising future growth. As of now, YIDU TECH has cumulatively repurchased over 180 million Hong Kong dollars for the year 2026. In terms of recent developments, YIDU TECH recently released the "MediMind Clinical Evidence-based Intelligent System", an AI product designed specifically for clinical doctors and medical researchers, focusing on the core pain points of diagnosis and treatment and relying on a massive amount of authoritative medical guidelines and literature to build a high-quality knowledge base. This system enables traceability of clinical decision evidence and precise adaptation of diagnosis and treatment recommendations, filling the gap in the field of clinical evidence-based AI and further improving the company's clinical intelligent product matrix. Furthermore, YIDU TECH recently entered the Boao Lecheng International Medical Tourism Pioneer Zone in Hainan, engaging in in-depth exchanges with local government officials. Through the continuous deepening of practical cooperation based on medical big data and AI-assisted diagnosis and treatment, the company has been deeply involved in the construction of the Lecheng Real-World Study Platform, accelerating the landing of innovative drugs and devices, and continuously advancing the digitization of grassroots medical care projects in Hainan, bridging key scenarios for the commercialization of AI medical services.